We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Capsaicin Patch 8 % for the Treatment of Persistent Pain After Inguinal Herniotomy

This study has been terminated.
(Expiration of the placebo patch)
ClinicalTrials.gov Identifier:
First Posted: October 4, 2012
Last Update Posted: February 26, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Joakim Bischoff, Rigshospitalet, Denmark
In the present study the investigators intend to investigate analgesic and sensory effects of a capsaicin patch 8 %(Qutenza) in patients with severe post-herniotomy pain and sensory abnormalities in the skin.

Condition Intervention Phase
Persistent Pain After Inguinal Herniotomy Drug: capsaicin patch (qutenza) Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Joakim Bischoff, Rigshospitalet, Denmark:

Primary Outcome Measures:
  • Pain change capsaicin vs. placebo patch treatment [ Time Frame: Pain intensity assessed at baseline and at 1,2,3 months follow-up ]
    Summed pain intensity (SPI) is calculated as median pain intensities at rest, during transition from the supine lying to the standing erect position, and auto-palpation twice each day for the last 3 days at baseline and at 1 months, 2 months and 3 months during follow-up. The primary outcome measure is the maximum difference between the summed pain intensity differences (SPID) for the phases: Baseline, 1 month, 2 month or 3 month. Δ SPID is then calculated as the difference in SPID between capsaicin and placebo treated patients.

Secondary Outcome Measures:
  • Changes in AAS (Activities Assessment Scale) score
  • Changes in HADS (Hospital Anxiety and Depression Scale) score
  • Changes in QST (Quantitative sensory testing)
  • Changes in sleep (Sleep Interference Scale) score
  • Changes in S-LANSS (Leeds self-assessment of neuropathic symptoms and signs)
  • Changes in intraepidermal nerve fiber density
  • Subgroup analysis for pain change(summed pain intensity differences (SPID) capsaicin patch vs. placebo are made for patients with thermal hypoesthesia and thermal normo/hyperesthesia
  • Changes in PCS (Pain Catastrophizing Scale) score

Other Outcome Measures:
  • interim analyses
    An interim analysis evaluating pain change (SPID) for capsaicin patch vs. placebo treatment by an independent statistician following completion of 32 patients.

Estimated Enrollment: 50
Study Start Date: August 2012
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: capsaicin patch Drug: capsaicin patch (qutenza)
Placebo Comparator: placebo patch Drug: Placebo


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients ASA (American Society´s of Anesthesiology´s classification) scores I-III
  • Severe post-herniotomy pain for more than six months and with severe pain (numerical rating scale [NRS] 0-10 points) during rest or during movement > 5.

Exclusion Criteria:

  • History of an allergic reaction or intolerance to capsaicin or vehicle ingredients in the patches
  • Severe cardiac impairment, e.g., NYHA (New York Heart Association) Class ≥ III
  • Inflamed or injured skin at the application site
  • Signs of cognitive impairment
  • Known drug or ethanol abuse
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01699854

Copenhagen, Copenhagen Ø, Denmark, 2100
Sponsors and Collaborators
Rigshospitalet, Denmark
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Joakim Bischoff, MD, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT01699854     History of Changes
Other Study ID Numbers: H-4-2012-055
2012-001540-22 ( EudraCT Number )
First Submitted: September 21, 2012
First Posted: October 4, 2012
Last Update Posted: February 26, 2014
Last Verified: February 2014

Additional relevant MeSH terms:
Dermatologic Agents
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs